Rezolute is trading at $4.48 (down 5.4%) as investors continue to digest the failed Phase 3 sunRIZE trial for ersodetug in congenital hyperinsulinism.
- The stock remains under pressure following an extreme selloff triggered by the trial disappointment and recent high volatility.
- Broader market sentiment is also weighing on the share price as the Nasdaq faces downward pressure today.